Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
In brief
JNJ’s new data show RYBREVANT is safer when given subcutaneously and more effective in a tough NSCLC subgroup, but the market remains wary.
ClearTape summarizes context in-app. For the full publisher article, use Read original source above.